
THERAPEUTIC APPROACH
HERVs as a source of tumor antigens
Human endogenous retroviruses (HERVs) represent a significant part of the human genome. HERVs are kept silent by epigenetic regulation but can be reactivated by malignant transformation or epigenetic therapies.
HERVs represent a reservoir of targetable antigens, especially in tumors with a low or moderate mutational burden.
Because HERV-derived antigens are seen as foreign, « virus-like » antigens, by the immune system, they represent relevant targets for the development of new cancer vaccines or T cell based therapies.
Our Pipeline
Our Breakthrough immunotherapies, combining cancer vaccines and T-cell therapie, have the potential to address high medical needs in oncology.
Cancer Vaccine
Discovery & Target validation
Pre-Clinical
Clinical
- TNBC 70%
- SARCOMA 40%
- OVARIAN CANCER 40%
- AML 40%
- GLIOBLASTOMA 40%
TCR-T
Discovery & Target validation
Pre-Clinical
Clinical
- EPITOPE 1 70%
- EPITOPE 2 70%
- EPITOPE 4 40%
- EPITOPE 6 40%

COLLABORATIONS & PARTNERSHIPS
Partnerships with world-class institutions
ErVimmune established strong partnerships with world-class institutions, to support its scientific innovation and development strategies, including @CRCL/Centre Léon Bérard “Development of immunotherapies targeting non-conventional tumor antigens” directed by Prof. Stéphane Depil.
To leverage ErVimmune development, a collaboration with Complete Omics (Baltimore, USA), a pioneer in proteomics, was launched on a neoantigen validation and quantification project in June 2021.
About ErVimmune
Medical research and development, in particular the development of new families of tumour antigens.
Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.
Useful links
> Publications & abstracts
> Recent news
> Legal notice
Navigation
> Home
> About us
> Sciences
> Investors
> Join us
> Contact
Contact
28 RUE LAENNEC
69008
LYON FRANCE
contact@ervimmune.com
+33 6 67 67 44 97
© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go